Although never directly compared in the context of anti-AML CAR T cells, the use of CD28 co-stimulatory domain may lead to shorter CAR T cell persistence and could therefore impact the duration of CAR T cell-induced myeloablation. Here, CD28 is linked to acute myeloid leukemia.